Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB2 | P47870 | 2/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 1/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | ALB | P02768 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | TSPO | P30536 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alpidem SCHEMBL16225062 | 0.89 | GABRB2 (0.78) | GABRB2GABRA1GABRA5NR1I2ABCB11 | |
| SCHEMBL20579952 | 0.80 | GABRA1 (0.66) | GABRB2GABRA1GABRA5KDM4ENPC1 | |
| SCHEMBL10754551 | 0.78 | GABRB2 (0.64) | GABRB2GABRA1GABRA5KDM4ENR1I2 | |
| SCHEMBL9752732 | 0.78 | GABRA1 (0.64) | GABRB2GABRA1GABRA5KDM4ENPC1 | |
| SCHEMBL1430614 | 0.78 | SLC2A2 (0.77) | GABRB2GABRA1GABRA5KDM4ENPC1 | |
| SCHEMBL7222041 | 0.77 | SLC2A2 (0.63) | GABRB2GABRA1GABRA5KDM4ENPC1 | |
| SCHEMBL8208 | 0.77 | KDM4E (0.64) | GABRB2GABRA1GABRA5KDM4ENPC1 | |
| SCHEMBL19807761 | 0.76 | KDM4E (0.67) | GABRB2GABRA1GABRA5KDM4ENPC1 | |
| SCHEMBL19807616 | 0.75 | KDM4E (0.66) | GABRB2GABRA1GABRA5KDM4ENPC1 | |
| SCHEMBL1691661 | 0.75 | KDM4E (0.69) | GABRB2GABRA1GABRA5KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414636-A1 | USE OF GABAA MODULATORS FOR TREATMENT OF RESPIRATORY CONDITIONS | SAGE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| WO-2022086835-A1 | COMBINATION PRODUCTS TO MITIGATE THE RISK OF NON-BENZODIAZEPINE BENZODIAZEPINE AGONIST ADVERSE REACTION AND OVERDOSE | PRESTI MICHAEL (US) | 2022-04-28 | — | — | WO | claimed |
| US-20220117916-A1 | Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose | SAFERX PHARMACEUTICALS LLC (US) | 2022-04-21 | — | — | US | claimed |
| WO-2021195301-A1 | USE OF GABAA MODULATORS FOR TREATMENT OF RESPIRATORY CONDITIONS | SAGE THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | claimed |
| US-20200339529-A1 | METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. HANS-KNÖLL-INSTITUT (HKI) (DE) | 2020-10-29 | — | — | US | claimed |
| EP-3713910-A1 | METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- (HKI) (DE) | 2020-09-30 | — | — | EP | claimed |
| WO-2019101679-A1 | METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. HANS-KNÖLL INSTITUT (HKI) (DE) | 2019-05-31 | — | — | WO | claimed |
| EP-3486229-A1 | METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- (HKI) (DE) | 2019-05-22 | — | — | EP | claimed |
| US-20170136127-A1 | HYDROGELS FOR TREATING AND AMELIORATING CANCERS AND POTENTIATING THE IMMUNE SYSTEM AND METHODS OF MAKING AND USING THEM | VICUS THERAPEUTICS LLC (US) | 2017-05-18 | — | — | US | claimed |
| EP-3164157-A2 | HYDROGELS FOR TREATING AND AMELIORATING CANCERS AND POTENTIATING THE IMMUNE SYSTEM AND METHODS OF MAKING AND USING THEM | Vicus Therapeutics, LLC (US) | 2017-05-10 | — | — | EP | claimed |
| CN-102300566-A | Cutaneous application of vasoconstrictors | — | 2011-12-28 | — | — | CN | claimed |
| EP-2376073-A2 | DERMAL APPLICATION OF VASOCONSTRICTORS | Zachar, Oron (IL) | 2011-10-19 | — | — | EP | claimed |
| US-20110158983-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | VICUS THERAPEUTICS, LLC | 2011-06-30 | — | — | US | claimed |
| US-20110144209-A1 | USE OF VASOCONSTRICTORS | ZACHAR ORON | 2011-06-16 | — | — | US | claimed |
| EP-2313037-A1 | DERMAL APPLICATION OF VASOCONSTRICTORS | Zachar, Oron (IL) | 2011-04-27 | — | — | EP | claimed |
| EP-2259844-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | Vicus Therapeutics SPE 1, LLC (US) | 2010-12-15 | — | — | EP | claimed |
| WO-2010063030-A2 | DERMAL APPLICATION OF VASOCONSTRICTORS | FEIGELSON, DANIEL (IL) | 2010-06-03 | — | — | WO | claimed |
| WO-2010001391-A1 | DERMAL APPLICATION OF VASOCONSTRICTORS | ZACHAR ORON (IL) | 2010-01-07 | — | — | WO | claimed |
| WO-2009111648-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | VICUS THERAPEUTICS, LLC (US) | 2009-09-11 | — | — | WO | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414636-A1 | USE OF GABAA MODULATORS FOR TREATMENT OF RESPIRATORY CONDITIONS | GABRB2, GABRB1, GABRA2 | GABRB2 1/4885GABRA1 5/4885GABRA5 6/4885 |
| US-20200339529-A1 | METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES | CBR3, POR, CYP2F1 | GABRB2 1666/4885GABRA1 2241/4885GABRA5 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.